Select Publications

METASTATIC DISEASE AS INITIAL PRESENTATION

23. Jubelirer SJ et al. Prognostic factors determining survival in breast cancer patients presenting with metastatic disease. W V Med J 1990;86(1):7-9. Abstract

24. Schorn C et al. MRI of the breast in patients with metastatic disease of unknown primary. Eur Radiol 1999;9:470-473. Abstract

25. Sherry MM et al. Breast cancer with skeletal metastases at initial diagnosis. Distinctive clinical characteristics and favorable prognosis. Cancer 1986;58(1):178-182. Abstract

TUMOR DORMANCY: IMPLICATIONS FOR MANAGEMENT OF THE PRIMARY TUMOR IN METASTATIC DISEASE

26. Flanigan RC et al. Cytoreduction nephrectomy in metastatic renal cancer: The results of Southwest Oncology Group trial 8949. Proc ASCO 2000; Abstract 3.

27 . Chambers AF et al. Critical steps in hematogenous metastasis: An overview. Surg Oncol Clin N Am 2001;10(2):243-55. Abstract

28. Demicheli R et al. Proposal for a new model of breast cancer metastatic development. Ann Oncol 1997;8(11):1075-80. Abstract

29. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995;1:27-31. Abstract

30. Holmgren L et al. Dormancy of micrometastases: Balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nat Med 1995;1:149-153. Abstract

31. Pinsolle V et al. Does surgery promote the development of metastasis in melanoma? Ann Chir Plast Esthet 2000;45(4):485-93. Abstract

32. Rak JW et al. Consequences of angiogenesis for tumor progression, metastasis and cancer therapy. Anticancer Drugs 1995;6:3-18. Abstract

HIGH-DOSE CHEMOTHERAPY FOR METASTATIC DISEASE

33. Baynes RD et al. High-dose chemotherapy and hematopoietic stem cell transplantation for breast cancer: Past or future? Semin Oncol 2001;28(4):377-88. Abstract

34. Berry DA et al. Conventional vs high-dose therapy for metastatic breast cancer: Comparison of Cancer and Leukemia Group B (CALGB) and Blood and Marrow Transplant Registry (ABMTR) patients. Proc ASCO 1999; Abstract 490.

35. Lotz JPet al. High-dose chemotherapy with hematopoietic stem cell transplantation for metastatic breast cancer: Results of the French protocol PEGASE 04. Proc ASCO 1999; Abstract 161.

36. Nieto Y et al. Status of high-dose chemotherapy for breast cancer: A review. Biol Blood Marrow Transplant 2000;6(5):476-95. Abstract

37. Peters WP et al. A large, prospective, randomized trial of high-dose combination alkylating agent (CPB) with autologous cellular support (ABMS) as consolidation for patients with metastatic breast cancer achieving complete remission after intensive doxorubicin-based induction therapy (AFM). Proc Am Soc Clin Oncol 1996:15:149a. No abstract available.

38. Peters WP et al. High-dose chemotherapy and peripheral blood progenitor cell transplantation in the treatment of breast cancer. Oncologist 2000;5(1):1-13. Abstract

39. Stadtmauer EA et al. Conventional-dose chemotherapy compared with high-dose chemotherapy plus autologous hematopoietic stem-cell transplantation for metastatic breast cancer. Philadelphia Bone Marrow Transplant Group. N Engl J Med 2000;342(15):1069-76. Abstract

COMBINATION THERAPY WITH LHRH AGONISTS

40. Boccardo F et al. Ovarian ablation versus goserelin with or without tamoxifen in pre-perimenopausal patients with advanced breast cancer: Results of a multicentric Italian study. Ann Oncol 1994;5:337-342. Abstract

41. Jonat W et al. A randomised study to compare the effect of the luteinising hormone-releasing hormone (LH-RH) analogue goserelin with or without tamoxifen in pre- and perimenopausal patients with advanced breast cancer. Eur J Cancer 1995;31:137-142. Abstract

42. Klijn JG et al. Combined tamoxifen and luteinizing hormone-releasing hormone (LH-RH) agonist versus LH-RH agonist alone in premenopausal advanced breast cancer: A meta-analysis of four randomized trials. J Clin Oncol 2001;19:343-53. Abstract

THIRD GENERATION AROMATASE INHIBITORS VERSUS TAMOXIFEN AS FIRST-LINE THERAPY

43. Bonneterre J et al. Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor-positive advanced breast carcinoma. Results of two randomized trials designed for combined analysis. Cancer 2001;92:2247-2258. No abstract available.

44. Nabholtz JM et al. Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: Results of a North American multicenter randomized trial. J Clin Oncol 2000;18(22):3758-3767. Abstract

45. Mouridsen H et al. Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: Results of a phase III study of the International Letrozole Breast Cancer Group. J Clin Oncol 2001;2596-2606. Abstract

THROMBOEMBOLISM IN BREAST CANCER PATIENTS

46. Ragaz J, Coldman A. Survival impact of adjuvant tamoxifen on competing causes of mortality in breast cancer survivors with analysis of mortality from contralateral breast cancer, cardiovascular events, endometrial cancer and thromboembolic episodes. J Clin Oncol 1998;16:2018-24. Abstract

47. Rickles FR, Levine MN. Venous thromboembolism in malignancy and malignancy in venous thromboembolism. Haemostasis 1998;28 Suppl 3:43-9. Abstract

48. Schmitt M, Kuhn W, Harbeck N, Graeff H. Thrombophilic state in breast cancer. Semin Thromb Hemost 1999;25:157-66. Abstract

GOSERELON AND ANASTROZOLE IN ADVANCED BREAST CANCER

49. Cheung KLet al. The combined use of goserelin and anastrozole as second-line endocrine therapy in premenopausal women with advanced breast cancer - a study of its clinical and endocrine effects. Proc ASCO 2001; Abstract 1937.

50. Forward D et al. Combined use of goserelin (Zoladex) and anastrozole (Arimidex) in premenopausal women with metastatic breast cancer (MBC). Proc ASCO 2000 ; Abstract 582.

EXEMESTANE AFTER PROGRESSION ON AN AROMATASE INHIBITOR

51. Lonning PE et al. Activity of exemestane in metastatic breast cancer after failure of nonsteroidal aromatase inhibitors: A phase II trial. J Clin Oncol 2000;18 ( 11):2234-44. Abstract

52. Thurlimann B et al. Third-line hormonal treatment with exemestane in postmenopausal patients with advanced breast cancer progressing on aminoglutethimide: A phase II multicentre multinational study. Exemestane Study Group. Eur J Cancer 1997;33(11):1767-73. Abstract

PACLITAXEL-INDUCTED PERIPHERAL NEUROPATHY

53. Michaud LB et al. Risks and benefits of taxanes in breast and ovarian cancer. Drug Saf 2000;23(5):401-28. Abstract

54. Vahdat L et al. Reduction of paclitaxel-induced peripheral neuropathy with glutamine. Clin Cancer Res 2001;7(5):1192-7. Abstract

TAXANES AND CAPECITABINE IN THE TRETMENT OF METASTATIC BREAST CANCER

55. Blum JL. The role of capecitabine, an oral, enzymatically activated fluoropyrimidine, in the treatment of metastatic breast cancer. Oncologist 2001;6(1):56-64. Abstract

56. Crown J. Docetaxel: Overview of an active drug for breast cancer. Oncologist 2001;6 Suppl 3:1-4. Abstract

57. Gradishar WJ. Clinical status of capecitabine in the treatment of breast cancer. Oncology (Huntingt) 2001;15(1 Suppl 2):69-71; discussion 72. Abstract

58. Michaud LB et al. Improved therapeutic index with lower dose capecitabine in metastatic breast cancer (MBC) patients (Pts). Proc ASCO 2000; Abstract 402.

59. Olin JJ, Muss HB. New strategies for managing metastatic breast cancer. Oncology (Huntingt) 2000;14(5):629-41; discussion 642-4, 647-8. Abstract

60. O'Shaughnessy J et al. A retrospective evaluation of the impact of dose reduction in patients treated with Xeloda (capecitabine). Proc ASCO 2000; Abstract 400.

61. Pivot X et al. The efficacy of chemotherapy with docetaxel and paclitaxel in anthracycline-resistant breast cancer. Int J Oncol 1999;15:381-6. Abstract

62. Stockler M et al. Systematic reviews of chemotherapy and endocrine therapy in metastatic breast cancer. Cancer Treat Rev 2000;26(3):151-68. Abstract

Home · Search